Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The employee equity awards vest over four annual installments, with each installment subject to continued employment.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Praxis Precision Medicines (PRAX) granted restricted stock units covering 3,478 common shares to new employees on October 1, 2026.
The awards went to fourteen non-executive employees under the 2024 Inducement Plan as inducements to join Praxis, in accordance with Nasdaq Listing Rule 5635(c)(4). They vest in four equal annual installments, subject to continued employment on each vesting date.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Restricted stock units covering 3,478 common shares create potential dilution as employee awards vest.
Key Figures
- Shares covered by awards
- 3,478 shares
- Restricted stock unit awards to new non-executive employees
- Recipients
- 14 employees
- New non-executive employees receiving awards
- Vesting schedule
- Four equal annual installments
- Subject to continued employment on each vesting date
Key Terms
restricted stock unit financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on October 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 3,478 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.
About Praxis
Praxis Precision Medicines is a fully integrated, leading CNS precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
Contacts: Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry LifeSci Advisors Daniel@lifesciadvisors.com 617-430-7576
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.